Zoetis Inc (ZTS)

Zoetis Inc (ZTS) stock tumbled by 7.84% due to a Wall Street Journal report noting some issues of the company's products. .

• Report Details: The report suggested that the animal pharmaceutical firm's arthritis treatment may have led to pet illnesses and deaths. The report highlighted concerns from some pet owners regarding Zoetis' Librela for dogs and Solensia for cats, the first antibody drugs for pets approved by the FDA.
• Regulatory Concerns: Regulators in the U.S. and Europe have received thousands of reports of side effects from the medications and are conducting reviews. Some veterinarians have changed their use of the treatments in response to these concerns. Zoetis responded to the report, stating that the drugs are "both safe and effective," and highlighting that over 18 million doses have been distributed, with low rates of adverse events reported.